Antithrombotic Therapy at the End of Life: The PEACE Study
For patients and families
In plain language
An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.
- What is being studied
- The protocol lists: antithrombotic drugs.
- Who it may be relevant to
- Registry conditions: Palliative Care. Basic parameters: from 18 years · All.
- What needs checking
- Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
- Where it takes place
- Italy
- Next step
- Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →
Unsure about the terms? Read our patient guide →
Overview
"Antithrombotic Therapy at the End of Life: The PEACE Study" is a multicenter, non-profit, cross-sectional observational study. In the absence of shared guidelines, therapeutic decisions on antithrombotic drugs vary significantly according to healthcare professional training and national context, resulting in marked variability in prescribing practices. This study aims to describe the prevalence of antithrombotic prescriptions in patients referred to Palliative Care.
Interventions
- Drug antithrombotic drugs
use of antithrombotic drug
Primary outcome measures
- Prevalence of antithrombotic drug use [Time frame: at enrollment]
Eligibility criteria
Inclusion criteria
- Adults (≥18 years) hospitalized and referred to Palliative Care (home-based or residential) at the discretion of the attending physician.
- Signed informed consent
Exclusion criteria
- none
Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.
Healthy volunteers: No
Study design
- Observational model
- Cohort
Study locations
Italy · 1 center
- Fondazione Policlinico Universitario Agostino Gemelli IRCCS — Roma
Identifiers
NCT: NCT07338071 · ID 3722